Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: Phase 3 study.

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ; Florbetaben Phase 3 Study Group.

Alzheimers Dement. 2015 Mar 28. pii: S1552-5260(15)00060-6. doi: 10.1016/j.jalz.2015.02.004. [Epub ahead of print]

2.

A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics.

Cornejo-Olivas MR, Torres L, Mata IF, Mazzetti P, Rivas D, Cosentino C, Inca-Martinez M, Cuba JM, Zabetian CP, Leverenz JB.

Parkinsonism Relat Disord. 2015 Jan 15. pii: S1353-8020(15)00023-1. doi: 10.1016/j.parkreldis.2015.01.005. [Epub ahead of print]

PMID:
25817512
3.

Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.

Bekris LM, Tsuang DW, Peskind ER, Yu CE, Montine TJ, Zhang J, Zabetian CP, Leverenz JB.

Mov Disord. 2015 Mar 24. doi: 10.1002/mds.26172. [Epub ahead of print]

PMID:
25808939
4.

Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease.

Madhyastha TM, Askren MK, Boord P, Zhang J, Leverenz JB, Grabowski TJ.

Mov Disord. 2015 Mar 11. doi: 10.1002/mds.26128. [Epub ahead of print]

PMID:
25759166
5.

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA; and the Parkinson's Progression Markers Initiative.

Mov Disord. 2015 Mar 4. doi: 10.1002/mds.26170. [Epub ahead of print]

PMID:
25737166
6.

TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models.

Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT.

J Exp Med. 2015 Mar 9;212(3):287-95. doi: 10.1084/jem.20142322. Epub 2015 Mar 2.

PMID:
25732305
7.

The biomarker and therapeutic potential of miRNA in Alzheimer's disease.

Bekris LM, Leverenz JB.

Neurodegener Dis Manag. 2015 Feb;5(1):61-74. doi: 10.2217/nmt.14.52.

PMID:
25711455
8.

PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease.

Beecham GW, Dickson DW, Scott WK, Martin ER, Schellenberg G, Nuytemans K, Larson EB, Buxbaum JD, Trojanowski JQ, Van Deerlin VM, Hurtig HI, Mash DC, Beach TG, Troncoso JC, Pletnikova O, Frosch MP, Ghetti B, Foroud TM, Honig LS, Marder K, Vonsattel JP, Goldman SM, Vinters HV, Ross OA, Wszolek ZK, Wang L, Dykxhoorn DM, Pericak-Vance MA, Montine TJ, Leverenz JB, Dawson TM, Vance JM.

Neurology. 2015 Mar 10;84(10):972-80. doi: 10.1212/WNL.0000000000001332. Epub 2015 Feb 6.

PMID:
25663231
9.

Cognitive profile of LRRK2-related Parkinson's disease.

Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP.

Mov Disord. 2015 Apr 15;30(5):728-33. doi: 10.1002/mds.26161. Epub 2015 Feb 4.

PMID:
25650144
10.

Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity.

Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Wang Y, Ginghina C, Liu C, Cain KC, Auinger P, Kang UJ, Jensen PH, Shi M, Zhang J.

Acta Neuropathol Commun. 2015 Jan 31;3(1):7. doi: 10.1186/s40478-015-0185-3.

11.

The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.

Liachko NF, McMillan PJ, Strovas TJ, Loomis E, Greenup L, Murrell JR, Ghetti B, Raskind MA, Montine TJ, Bird TD, Leverenz JB, Kraemer BC.

PLoS Genet. 2014 Dec 4;10(12):e1004803. doi: 10.1371/journal.pgen.1004803. eCollection 2014 Dec.

12.

Lower plasma Apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype.

Swanson CR, Li K, Unger TL, Gallagher MD, Van Deerlin VM, Agarwal P, Leverenz J, Roberts J, Samii A, Gross RG, Hurtig H, Rick J, Weintraub D, Trojanowski JQ, Zabetian C, Chen-Plotkin AS.

Mov Disord. 2014 Sep 16. doi: 10.1002/mds.26022. [Epub ahead of print]

PMID:
25227208
13.

Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study.

Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, Baldwin CT, Jarvik GP, Crane PK, Rogaeva E, Barmada MM, Demirci FY, Cruchaga C, Kramer PL, Ertekin-Taner N, Hardy J, Graff-Radford NR, Green RC, Larson EB, St George-Hyslop PH, Buxbaum JD, Evans DA, Schneider JA, Lunetta KL, Kamboh MI, Saykin AJ, Reiman EM, De Jager PL, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Martin ER, Haines JL, Mayeux RP, Farrer LA, Schellenberg GD, Pericak-Vance MA; Alzheimer Disease Genetics Consortium, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barnes LL, Beach TG, Becker JT, Beekly D, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carrasquillo MM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cribbs DH, Crocco EA, DeCarli C, DeKosky ST, Dick M, Dickson DW, Duara R, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lin CF, Lopez OL, Lyketsos CG, Mack WJ, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Murrell JR, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Valladares O, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Wishnek S, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L.

JAMA Neurol. 2014 Nov;71(11):1394-404. doi: 10.1001/jamaneurol.2014.1491. Erratum in: JAMA Neurol. 2014 Nov;71(11):1457.

14.

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.

PMID:
25178429
15.

People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance.

Burdick DJ, Cholerton B, Watson GS, Siderowf A, Trojanowski JQ, Weintraub D, Ritz B, Rhodes SL, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Srivatsal S, Edwards KL, Montine TJ, Zabetian CP, Leverenz JB.

Mov Disord. 2014 Sep;29(10):1258-64. doi: 10.1002/mds.25924. Epub 2014 Jul 29.

PMID:
25073717
16.

Influence of lifestyle modifications on age-related free radical injury to brain.

Peskind ER, Li G, Shofer JB, Millard SP, Leverenz JB, Yu CE, Raskind MA, Quinn JF, Galasko DR, Montine TJ.

JAMA Neurol. 2014 Sep;71(9):1150-4. doi: 10.1001/jamaneurol.2014.1428.

PMID:
25048271
17.

The neurobiological basis of cognitive impairment in Parkinson's disease.

Halliday GM, Leverenz JB, Schneider JS, Adler CH.

Mov Disord. 2014 Apr 15;29(5):634-50. doi: 10.1002/mds.25857. Review.

18.

Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span.

Li G, Millard SP, Peskind ER, Zhang J, Yu CE, Leverenz JB, Mayer C, Shofer JS, Raskind MA, Quinn JF, Galasko DR, Montine TJ.

JAMA Neurol. 2014 Jun;71(6):742-51. doi: 10.1001/jamaneurol.2014.445.

PMID:
24756381
19.

Evaluation of mild cognitive impairment subtypes in Parkinson's disease.

Cholerton BA, Zabetian CP, Wan JY, Montine TJ, Quinn JF, Mata IF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Leverenz JB, Edwards KL.

Mov Disord. 2014 May;29(6):756-64. doi: 10.1002/mds.25875. Epub 2014 Apr 7.

20.

Clinical and molecular studies reveal a PSEN1 mutation (L153V) in a Peruvian family with early-onset Alzheimer's disease.

Cornejo-Olivas MR, Yu CE, Mazzetti P, Mata IF, Meza M, Lindo-Samanamud S, Leverenz JB, Bird TD.

Neurosci Lett. 2014 Mar 20;563:140-3. doi: 10.1016/j.neulet.2014.01.016. Epub 2014 Feb 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk